Recently, a delegation led by Ms. Lucia Rizka Andalucia, Acting Head of Indonesia’s National Agency for Drug and Food Control (Indonesian: Badan Pengawas Obat and Makanan, the “BPOM”), accompanied by Sie Djohan, President Director of PT Kalbe Genexine Biologics (“KGbio”), visited Henlius. Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, warmly received the delegation and extended a sincere welcome.
During the meeting, Dr. Zhu presented Henlius' development history, core businesses, research progress, and future strategic plans. He highlighted the company's innovative achievements and market advantages in the field. The two sides also discussed potential future collaborations in detail. Following the meeting, the Indonesian delegation toured Henlius' Xuhui Facility to observe the company's production processes and commercial production capabilities firsthand.
Ms. Lucia Rizka Andalucia praised Henlius for its advanced innovations and quality management system, which aligns with international standards. She emphasized BPOM's commitment to international collaboration and expressed hope that KGbio would continue to work closely with Henlius on products to advance the biopharmaceutical industry in Indonesia and improve local patient accessibility.
In December 2023, HANSIZHUANG was approved in Indonesia under the trade name Zerpidio®, becoming the first Chinese anti-PD-1 mAb approved in Southeast Asia. In January 2024, Henlius successfully completed the first overseas shipment of HANSIZHUANG, marking a new chapter in making the product accessible to patients worldwide. Since 2019, Henlius has been collaborating with KGbio to progressively expand collaboration in 22 emerging market countries across Southeast Asia, Middle East and North African (MENA) countries regarding HANSIZHUANG. The two parties are actively working towards obtaining approvals in more countries, aiming to bring advanced and efficient treatment options to local patients.
The visit by the Indonesian BPOM and KGbio not only underscores Henlius' commitment to global expansion but also strengthens the mutual trust and collaboration between Henlius, Indonesian BPOM, and KGbio. This visit lays a solid foundation for further collaboration in the future.
Moving forward, Henlius will continue to strive for technological innovation and global collaboration, accelerating the provision of affordable, high-quality biologics for patients worldwide.